Mouse VEGFR2/KDR/Flk-1 Antibody

Catalog #: MAB4431
6 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB4431-SP
MAB4431-100
MAB4431-500

VEGFR2/KDR/Flk‑1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGFR2/KDR/Flk‑1 Antibody.

1 Image

Product Details

Citations (6)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse VEGFR2/KDR/Flk-1 Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse VEGFR2 in Western blots.

Source

Monoclonal Rat IgG_2A Clone # 91202

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2
Ala20-Glu762
Accession # P35918

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Mouse VEGFR2/Flk-1 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Mouse VEGFR2/KDR/Flk-1 Biotinylated Antibody (Catalog # BAF644)

Standard: Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein (Catalog # 443-KD)

Neutralization

Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND₅₀) is typically 0.05-0.15 µg/mL in the presence of 150 ng/mL Recombinant Mouse VEGFR2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Mouse VEGF₁₆₄.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

VEGFR2/KDR/Flk‑1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGFR2/KDR/Flk‑1 Antibody. Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (Catalog # 443-KD) inhibits Recombinant Mouse VEGF₁₆₄(Catalog # 493-MV) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse VEGF₁₆₄(5 ng/mL) activity elicited by Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (150 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGFR2/KDR/Flk-1 Monoclonal Antibody (Catalog # MAB4431). The ND₅₀ is typically 0.05-0.15 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) precursor protein with a 19 aa signal peptide. Mature VEGFR2 is composed of a 743 aa extracellular domain, a 22 aa transmembrane domain, and a 583 aa cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA 95:548.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Alternate Names

CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Mouse VEGFR2/KDR/Flk-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

A glycan-based approach to therapeutic angiogenesis
Authors: Jie Shi Chua, Vy M. Tran, Mausam Kalita, Maritza V. Quintero, Orlando Antelope, Geethu Muruganandam et al.
PLOS ONE
Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization
Authors: FA Rossato, Y Su, A Mackey, YSE Ng
Cells, 2020-09-09;9(9):.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization
Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination
Sci Rep, 2016-09-12;6(0):33162.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Authors: Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M
J Exp Med, 2015-01-19;212(2):139-48.
Species: Mouse
Sample Types: Whole Cells
Applications: Neutralization
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.
Authors: Nagai, Norihiro, Lundh von Leithner, Pete, Izumi-Nagai, Kanako, Hosking, Brett, Chang, Bo, Hurd, Ron, Adamson, Peter, Adamis, Anthony, Foxton, Richard, Ng, Yin Shan, Shima, David T
Invest Ophthalmol Vis Sci, 2014-05-20;55(6):3709-19.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization
alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
Authors: Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
Blood, 2007-11-27;111(4):1980-8.
Species: Mouse
Sample Types: Cell Lysates, Whole Cells, Whole Tissue
Applications: ICC, IHC-Fr, Neutralization, Western Blot